PALO ALTO, CA, USA I April 15, 2025 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...

Late-breaking oral presentation to include full Phase 1b results for TX45 in the Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”) cohortWATERTOWN, Mass., ...

Capital will Support Continued Development of First-in-Class GPR35 Inhibitor Program for the Treatment of Ulcerative Colitis Utilizing Biomarker-D ...

Dr Morgan Li, Dr Alexandre Siqueira, Dr Sarah Piper, Dr Marcus Giansiracusa and Dr Laura Williams. Images supplied.Five ...